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Synthetic androgens suppress the transformed phenotype in the human
prostate carcinoma cell line LNCaP
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Summary Experiments have been designed to investigate hormonal effects on the human prostatic carcinoma
cell line LNCaP in the presence of complete foetal calf serum. At physiological concentrations (3.3 x 10- M),
several derivatives of 17a-methyl-testosterone led to a significant reduction of cell proliferation, inhibition of
colony formation in soft agar, change of morphology, induction of a prostate specific mRNA and down-
regulation of c-myc RNA. Two different antiandrogens, hydroxyflutamide and cyproterone acetate, were
capable of reversing the effects exerted by the synthetic androgens on growth properties. The proliferation rate
ofcontrol cells devoid ofandrogen receptor was not inhibited by synthetic androgens. Our results indicate that
the cellular androgen response mechanism of LNCaP cells is intact and that synthetic androgens elicit
androgen receptor mediated suppression of the transformed phenotype. Rare cases of remission of prostatic
cancer on androgen treatment have been reported. LNCaP cells may be a model of an uncommon class of
prostatic cancer which responds favourably to androgen treatment.
Tumour suppression by exogenous agents has become an
area of intense research (Lippman et al., 1987; Waxman et
al., 1988). Hormone-responsive malignancies like prostate
cancer were the first targets of tumour-suppressive hormonal
manipulations (Huggins & Hodges, 1941). Although a large
body of information has accumulated on the mode of action
of steroid hormones in the regulation of individual genes, the
biological basis of androgen-dependence of normal and
malignant prostatic tissue and the modulation of cell pro-
liferation by natural steroids remain to be elucidated. The
aim of the present study was to characterise the response of
human prostatic carcinoma cells to different androgens in
terms of growth properties, morphology, expression of the
transformed phenotype, and regulation of a prostate specific
gene.
A number of cell lines of prostatic origin has been estab-
lished (Stone et al., 1978; Kaighn et al., 1979; Horoszewicz et
al., 1980). The LNCaP cell line (Horoszewicz et al., 1980)
which retains functional properties of normal prostatic
epithelial cells is regarded as the best-suited in vitro model of
prostate cancer available. LNCaP cells synthesise at least
three prostate specific proteins, i.e. prostate specific acid
phosphatate (Horoszewicz et al., 1983; Schulz et al., 1985),
prostate specific antigen (PSA; Schulz et al., 1988), and the
antigen reactive with the monoclonal antibody KR-P8
(Raynor et al., 1984), and they contain an androgen receptor
(Horoszewicz et al., 1983) which has recently been reported
to carry a mutation in the steroid binding domain (Veld-
scholt et al., 1990b).
Hormone effects on LNCaP cells have been investigated in
cell culture and in nude mice (Horoszewicz et al., 1980;
Sonnenschein et al., 1989). Many cell culture studies used
charcoal-stripped foetal calf serum (FCS; van Steenbrugge et
al., 1989; Berns et al., 1986; Schuurmans et al., 1988a-c;
Schuurmans et al., 1989; Wilding et al., 1989) to control the
concentration of steroids in the medium rigorously. The
results obtained with charcoal-stripped foetal calf serum
(FCS) demonstrate biphasic androgen induction of epidermal
growth factor-receptor and growth stimulation of LNCaP
cells. At concentrations below 10-1lM, the synthetic andro-
gen methyltrienolone (R1881) stimulates proliferation in a
dose-dependent manner, above this threshold growth stimu-
lation decreases (Berns et al., 1986).
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Although charcoal-stripping of FCS provides the oppor-
tunity to create a more defined and reproducible hormonal
environment, indiscriminate removal of hydrophobic sub-
stances may be detrimental to cell viability and only poorly
reflect the in vivo situation (Horoszewicz et al., 1983). The
proliferation of LNCaP cells is severely inhibited in medium
containing charcoal-stripped serum (Sonnenschein et al.,
1989), and according to the majority of published studies,
androgens cannot fully compensate the effect of charcoal
treatment (van Steenbrugge et al., 1989). It appears ques-
tionable, whether experiments conducted with delipidated
FCS are appropriate to support the view that LNCaP cells
are a model of androgen-dependent cancer. Androgen
dependence of prostatic cancers in vivo is seen with the full
complement of growth factors and physiological stimuli
available to the cells. In our experiments, complete FCS was
used throughout.
To prevent androgen metabolism which would rapidly
alter the hormonal environment, to which the cells are
exposed, we used non-metabolisable synthetic androgens
(Bonne & Raynaud, 1976) with 17a-methyl-testosterone as
the basic structure. These substances were expected to act as
powerful androgens providing a constant hormonal stimulus
to the cultured cells.
In contrast to studies using delipidated FCS, we found no
indication of androgen dependence of hormone responsive
LNCaP cells. According to commonly used in vitro
parameters, the transformed phenotype of LNCaP cells is
suppressed by synthetic androgens. This cell line may be a
model of an uncommon type of prostate cancer which re-
sponds favourably to androgen therapy.
Materials and methods
Cell lines andhormones
All lines used in this work are of human origin. The prostate
carcinoma lines LNCaP (Horoszewicz et al., 1980), PC-3
(Kaighn et al., 1979), and DU 145 (Stone et al., 1978) were
from the Human Tumor Cell Laboratory, Sloan Kettering
Institute for Cancer Research, Rye, NY, and MRC-5 (em-
bryonal lung, nontransformed with limited lifetime) was from
Flow Laboratories. LNCaP cells between passages 75 and 90
were used for the experiments described.
Natural androgen dihydrotestosterone (DHT; Sigma
Chemical Co.).
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Synthetic androgens 7a-17a-Dimethyl-19-nortestosterone (mi-
bolerone; Upjohn); 17frhydroxy-17o-methyl-estra4,9,11-trien-
3-one (methyltrienolone, R1881; Roussel Uclaf). lo-17a-
Dimethyl-testosterone (Sch A), la-7a-17a-Trimethyl-test-
osterone (Sch B), and 7a-17a-Dimethyl-testosterone (Sch C)
were a generous gift of Schering AG, Berlin, Germany.
Antiandrogens 6-chloro-6-dehydro-17x-acetoxy-hla, 2a-methyl-
ene-progesterone (cyproterone acetate, CA; Schering); 2-
methyl-2-hydroxy-N-[4-nitro-3-(trifluoromethyl)phenyl] pro-
panamide (hydroxyflutamide, Flu-OH; Essex).
Cell culture and assaysfor inhibition ofproliferation
Assays were carried out with media containing 10% complete
FCS as described in detail (Schulz et al., 1988a). The cell line
LNCaP was maintained in RPMI medium, and the lines
PC-3, DU 145, and MRC-5, in DMEM. All lines were grown
as monolayers in the presence of 10% FCS and phenol red.
All cell lines reached near or complete confluence before
being split, except PC-3, which was kept at lower density.
For the preparation of seed stocks, cells were grown to 50 to
75% confluency before use. The period between splitting and
seeding for growth inhibition assays of the individual cell
lines was: LNCaP (3 to 4 days); PC-3 (2 to 3 days); DU 145
(3 to 4 days); and MRC-5 (6 to 7 days). To assay effects on
proliferation cells were seeded into 60 mm Petri dishes in
8 ml of culture medium. The inoculum sizes were held con-
stant within cell lines and were as follows: LNCaP (7 x 105);
PC-3 (5 x 105); DU 145 (7 x 105); and MRC-5 (7 x 105).
Hormones were added 16 to 24 h after seeding as 20g1l
ethanol solutions to give the final concentrations indicated in
the figures. After 120 h of incubation of controls and hor-
mone containing samples, cells were trypsinised and cell
numbers were determined manually in at least six dishes
incubated in parallel with the respective hormones.
Assayfor anchorage-independent growth
Agar Noble (Difco) was suspended at 0.75% in water, auto-
claved, and cooled to 60°C. 1/10 volune of 10-fold concen-
trated Dulbecco's medium and 1/10 volume of FCS were
added, and 3 ml of this solution (0.6% agar) were poured
into a culture dish of 60 mm diameter. Trypsinised LNCaP
cells were counted and 2 x 104 cells were suspended in 1 ml
of Dulbecco's medium supplemented with the 2-fold final
hormone concentration. The agar solution (1 ml) described
above was added to 1 ml of the cell suspension and poured
immediately into a culture dish containing hardened bottom
agar. After 6 days of incubation, the cells were fed with 3 ml
of fresh medium supplemented with the respective hormones.
Colonies of more than 50 ftm in diameter were scored in
triplicate after 10-12 days.
Table I Cell numbers (LNCaP) in andrc
co]
Northern blots
Total cellular RNA was isolated by selective precipitation
twice with 3 M LiCl, 6 M urea followed by one phenol extrac-
tion (Auffray & Rougeon, 1980) and two precipitations with
3 M sodium acetate, pH 6.0. High molecular weight DNA
was sheared mechanically (Ultra-Turrax) before the first cen-
trifugation. RNA samples (20 jig per lane) were denatured by
incubation with 50% formamide and 6% formaldehyde at
60°C for 20 min and subsequently separated on 1.2% agarose
gels containing 6% formaldehyde. Integrity and relative
amounts of RNA per lane were checked by staining with
ethidium bromide. 28 S and 18 S rRNAs were used as inter-
nal size markers. RNAs were blotted on to 'biodyne' nylon
membranes (manufactured by PALL) and baked for 2 h in a
vacuum oven. Filters were prehybridised in 5-fold concen-
trated standard saline citrate (SSC; 1 x SSC: 150 mM
NaCl, 15 mM Na3-citrate), 0.5% SDS, 1 x Denhardt's solu-
tion (1 x Denhardt: 0.2 g 1' polyvinylpyrrolidone, 0.2 g 1'
Ficoll, 0.2 g1` bovine serum albumin), and hybridisation
was carried out for 20 h at 68'C in 5 ml of the same solution
contianing 1.5 x 106 c.p.m. ml-Iof a PSA specific probe. 32p_
labelling was performed with the random primed labelling kit
(Boehringer Mannheim) according to the recommendations
of the supplier. The 1.4 kilobase EcoRI/BamHI fragment
derived from a PSA specific cDNA clone (Schulz et al.,
1988b) was chosen as a hybridisation probe. It spans the
coding region of the complete mature PSA protein. The
probe specific for the housekeeping enzyme phosphoglycerate-
kinase (Michelson et al., 1983) was a 1.8 kilobase PstI frag-
ment encompassing the complete cDNA sequence, and the
c-myc probe was a 1.4 kb EcoRI/Clal fragment covering the
3rd exon (Eick et al., 1985). Filters were washed at 68°C once
in 4 x SSC, 0.5% SDS, 1 x Denhardt's solution for 30 min,
twice 15 min in 2 x SSC, 0.5% SDS, 30 min in 2 x SSC, and
subsequently exposed 40 h at - 80°C to Fuji X-ray films
between intensifier screens.
Results
Inhibition ofproliferation in androgen receptorpositive
LNCaP cells
In complete FCS, synthetic androgens containing a 17a-
methyl-testosterone backbone consistently inhibit the pro-
liferation of LNCaP cells at physiological concentrations,
while the natural androgen DHT is effective ony at a 1,000-
fold higher concentration, and, in fact, does not achieve the
same degree of inhibition as the synthetic compounds (Table
I). The weak effect of DHT is probably due to its rapid
metabolism to polar compounds (Berns et al., 1986). After
120h of incubation, the cell number in samples containing
:gen containing samples relative to untreated
ntrols
Hormone
concentration,
x 10-9m: 0 0.165 0.33 3.3 33 330 3300
Hormone
DHT 100 98 (2.8) 94 (4.1) 89 (4.9) 77 (2.8) 67 (4.9) 50 (5.6)
Mibolerone 100 55 (4.2) 44 (6.6) 23 (0.9) 29 (4.0) 27 (3.4) 30 (4.2)
R1881 100 50 (10.7) 32 (7.7) 32 (7.7) 31 (5.5) 37 (4.7) 31 (5.0)
Sch A 100 65 (12) 50 (9.0) 27 (4.5) 27 (5.4) 27 (4.7) 28 (5.8)
Sch B 100 49 (6.6) 39 (5.0) 33 (3.0) 26 (6.3) 29 (3.1) 28 (5.4)
Sch C 100 46 (9.0) 37 (8.0) 29 (6.2) 26 (6.5) 26 (7.6) 28 (4.9)
Values represent the cell number in hormone containing samples as per cent of the cell
number of untreated controls which are defined as 100%. The standard deviation is given in
brackets. Equal cell numbers were seeded into cell culture dishes, the medium was
supplemented with the respective hormones, and after 120 h of incubation the cell numbers
were determined manually. Each value represents the mean and standard deviation of at least
six independent determinations.SUPPRESSION OF THE TRANSFORMED PHENOTYPE BY ANDROGENS 49
3.3 X 10- M or more of synthetic androgens is only 25-35%
of controls. Saturation of growth inhibition is reached at
3.3 x 10-9M of synthetic androgen. Below this value the
effect is concentration dependent. In order to exclude a
general cytotoxic effect of synthetic androgens on cultured
cells, control lines were exposed to synthetic androgens at
concentrations effective toward LNCaP cells. Cell lines
devoid of androgen receptor (PC-3, DU 145, MRC-5) were
completely unresponsive (Table II). Neither the growth rate
nor the morphology of control cell lines was modulated.
Antiandrogens antagonise androgen effects on LNCaP
proliferation
In order to examine, whether the growth inhibition of
LNCaP cells is in fact mediated by the androgen receptor, we
attempted to antagonise it by antiandrogens. CA and Flu-
OH compete with androgens for binding of the androgen
receptor (Wakeling et al., 1981) and are capable of reversing
the androgen-induced inhibiton of proliferation, if added in
several hundred-fold excess over the androgen (1.8 x 10-6 M
CA, 2.6 x 10-6 M Flu-OH; Figure 1). The large amount of
antiandrogens required is explained by their relatively low
affinity to the androgen receptor (Wakeling et al., 1981). At
the concentrations used, antiandrogens alone hardly affect
the proliferation of LNCaP cells (Figure 1). These findings
clearly demonstrate that LNCaP cells are not androgen-
dependent, and that the growth inhibition by synthetic
androgens is mediated by the androgen receptor.
MIB - 1 1 - 1 -
CA - 750 750
FLU-OH - - - - 750 750
(ng ml-)
Figure 1 Antiandrogens counteract the androgen-induced inhibi-
tion of proliferation in LNCaP. Cell numbers after 120 h of
incubation in hormone-containing dishes are given in per cent of
controls (r). Values are means (s.d.) of at least 6 determinations.
MIB, 1 ngm;-': mibolerone, 3.3 x 1O-9M; CA, 750ngml-':
cyproterone acetate, 1.8 x 10-6 M; FLU-OH, 750 ng ml-': hyd-
roxyflutamide, 2.6 x 10-6 M.
Change ofmorphology
Synthetic androgens cause a remarkable change in cell shape
and size of LNCaP cells. In the presence of mibolerone,
LNCaP cells enlarge and look less asteroid than control cells
(Figure 2). The morphological changes induced by
mibolerone are antagonised by antiandrogens.
Induction ofandrogen responsive PSA mRNA and
down-regulation ofgrowth-related c-myc RNA
To investigate, if the androgen response machinery of
LNCaP cells is functional in modulating the expression of
individual genes, the androgen effect on the level of PSA
mRNA was examined in Northern blots. PSA-specific
mRNA was markedly induced by the synthetic androgen
mibolerone. Stimulation by two antiandrogens, CA and Flu-
OH, was less pronounced. When the synthetic androgen and
excess antiandrogen were applied simultaneously, the
stimulation was reduced to the level seen with antiandrogens
alone (Figure 3).
The expression of c-myc RNA and protein has been
strongly implicated in the control of cell growth and
differentiation (for review see Spencer & Groudine, 1990). In
many cell types, inhibition of proliferation or induction of
terminal differentiation is accompanied by down-regulation
of c-myc. Therefore, we examined the effect of the synthetic
androgen mibolerone on c-myc RNA expression in LNCaP
cells. As shown in Figure 3, the steady-state level of c-myc
RNA clearly decreases compared to a housekeeping mRNA.
In the presence of excess antiandrogens, no change of c-myc
RNA levels is detectable. C-myc expression and proliferative
activity appear to be coupled in LNCaP cells. Work is in
progress to determine the type of control governing the
down-regulation of c-myc by mibolerone.
Inhibition ofanchorage-independent growth
Contact inhibition of cell proliferation and anchorage-
independent growth are regarded as important parameters of
the malignant phenotype of cells cultured in vitro (Freedman
& Shin, 1974; Pollack et al., 1984). Although in the presence
of synthetic androgens, LNCaP cells constantly grew more
slowly than control cells over prolonged periods of incuba-
tion, they did not show a clear-cut contact inhibition, as
determined by long-term culture (data not shown). In con-
trast, when assayed for the ability of colony formation in soft
agar, synthetic androgens drastically suppressed the growth
potential of LNCaP cells (Figure 4). The number of colonies
was reduced by a factor of between 50 to 500, i.e. to less
than 1% of controls. The natural androgen DHT also inhibited
anchorage-independent growth, but at 3.3 x 10- M the col-
ony number was still 39% of controls. A concentration of
3.3 x 10-7 M of DHT was required to reduce the cloning
Table II Cell numbers (androgen receptor-negative cell lines PC-3,
DU 145, and MRC-5; for comparison LNCaP) in mibolerone containing
samples relative to untreated controls
Hormone
concentration,
x l0o9 M: 0 3.3 33 330 3300
Cell line
PC-3 100 91 (6.8) 93 (11.3) 93 (4.7) 79 (6.2)
DU145 100 108 (8.3) 92 (11.2) 107 (7.5) 102 (7.6)
MRC-5 100 107 (9.3) 100 (2.1) 107 (6.7) 108 (9.40
LNCaP 100 23 (0.9) 29 (4.0) 27 (3.4) 30 (4.2)
Values represent the cell number in hormone containing samples as per
cent of the cell number of untreated controls which are defined as 100%.
The standard deviation is given in brackets. Equal cell numbers were seeded
into cell culture dishes, the medium was supplemented with the respective
hormones, and after 120 h of incubation (192 h for MRC-5 cells) the cell
numbers were determined manually. Each value represents the mean and
standard deviation of at least six independent determinations.50 D.A. WOLF et al.
Flu-OH
CA
MIB
PSA
c-myc
PGK
. .
- - - - - 750750
- - - - - 750750 - -
- 1 10 10010001 - 1 -
(ngml')
-28S
-18S
-28S
-18S
Figure 3 Mibolerone raises the level of PSA specific mRNA
while repressing c-myc RNA. RNA was extracted as described
after 48 h of incubation of LNCaP cells in the presence of the
respective hormones. MIB, 1 ngml-': mibolerone, 3.3 x 1O-9M;
CA, 750 ng ml-': cyproterone acetate, 1.8 x 10-6M; FLU-OH,
750 ng ml-X: hydroxyflutamide, 2.6 x 10-6 M. PGK, phosphogly-
cerate kinase.
X
6
A . ,.£
100
50
MIB R1881 SchA Sch B SchC
Figure 2 Synthetic androgens induce morphological changes in
LNCaP cells. LNCaP cells were grown a, for 120 h without
hormones, b, in the presence of 3.3 x 10-9 M mibolerone, and c,
in the presence of 3.3 x 10-9M mibolerone plus 1.8 x 10-6M CA.
Magnification 560 x; bar, 10 m.
efficiency in soft agar to 0.6% of control cells (data not
shown). Antiandrogens again counteracted the inhibition of
anchorage-independent growth (Figure 4).
As shown in Figure 5, control LNCaP cells form large
colonies in soft agar, while in the presence of mibolerone
only occasional very small colonies are seen. When anti-
androgen is applied simultaneously, the soft agar colonies
reach about half the size as in control samples, and are less
dense. The transformed behaviour in vitro is partially
restored by CA and Flu-OH.
Discussion
The androgen analogues were capable of inducing five dis-
tinct androgen effects (reduction of proliferation, inhibiton of
anchorage-independent growth, change of morphology,
induction of prostate specific mRNA and repression ofc-myc
RNA) on LNCaP cells to the full extent, a concentration of
3.3 x 1O-9M being maximally effective. All growth-related
effects were clearly antagonised by excess antiandrogens
ANDROGEN
(1 ng ml 1)
CA (750 ng ml-1)
FLU-OH
(750 ng ml-1)
_ +++ +++ ±±±
_ -+ - +- _ -_+
+++ ++ + _-
_+-
_ ±+ + _
_ - + --+ --+ _-+ - +
Figure 4 Synthetic androgens suppress colony formation of
LNCaP cells in soft agar, and antiandrogens restore anchorage-
independent growth. Colony numbers (means of at least 6
determinations) scored after 10-12 days of culture in hormone
containing samples are represented as per cent of controls (r).
For mibolerone, Rl881, Sch B, and Sch C the value was less than
one per cent and could not be accurately depicted. MIB,
1 ngml-: mibolerone, 3.3 x 10-9M; SchA, 1 ngml'-: ax-17a-
Dimethyl-testosterone, 3.3 x l0-9M; Sch B, 1 ngml-': la-7a-17a-
Trimethyl-testosterone, 3.3 x 10-9M; Sch C, 1 ngml-':
7a-17a-Dimethyl-testosterone, 3.3 x 10-9M; CA, 750 ngml -:
cyproterone acetate, 1.8 x 10-6M; FLU-OH, 750 ngml-': hy-
droxyflutamide, 2.6 x 10-6 M.
which compete for androgen receptor binding. The identical
dose-response behaviour suggests that all five phenomena are
mediated by the same androgen receptor-dependent signal
transducing mechanism.
The androgen receptor content of LNCaP cells appears to
vary markedly among different sublines (Horoszewicz et al.,
1983: 153 and 266 fmolmg-' cytosolic protein; Sonnenschein
et al., 1989: 68 fmolmg-' cytosolic protein; Schuurmans et
al., 1988c: 920 fmol mg-' cytosolic protein), and even the
existence of androgen-resistant sublines of LNCaP has been
demonstrated (Hasenson et al., 1985; van Steenbrugge et al.,
1989). The androgen receptor level of our stock of LNCaP
cells was between 25 and 38 fmol mg-' cytosolic protein
.-- - L
.X.
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Figure 5 Mibolerone inhibits colony formation of LNCaP cells
in soft agar. LNCaP cells were grown for 10 days in soft agar, a,
without hormones, b, in the presence of 3.3 x 10- M mibolerone,
and c, in the presence of 3.3 x 10' M mibolerone plus
1.8 x 10-6 M CA. Magnification 100 x; bar, 100 lim.
(H. Bojar, University of Dusseldorf, personal communica-
tion). Therefore we examined, whether the androgen-
dependent signal transduction pathway in LNCaP cells could
trigger induction of a prostate specific mRNA. The level of
PSA mRNA was clearly elevated in the presence of
3.3 x l0- M of the synthetic androgen mibolerone, and was
also increased in the presence of high doses of antiandrogens
(1.8 x 10-6 M CA or 2.6 x 10-6 M Flu-OH; Figure 3). The
simultaneous application of mibolerone and CA or Flu-OH
did not result in synergistic enhancement of PSA transcrip-
tion, but antiandrogens reduced androgen induction of PSA
mRNA. Although both androgens and antiandrogens showed
agonistic activity on PSA induction, they appear to compete
for receptor binding and to cancel each other's activity.
Since the PSA promoter contains a consensus sequence of
steroid receptor binding sites (Klobeck et al., 1989), nuclear
run-on experiments were conducted to show that enhanced
transcription is indeed responsible for this hormone effect
(D.A. Wolf, unpublished).
Recently, an amino acid change in the steroid binding
domain of the LNCaP androgen receptor was found to result
in an abnormallly high affinity of this receptor to CA and in
stimulation of transcription by CA from a promoter contain-
ing a glucocorticoid responsive element (Veldscholte et al.,
1990a,b). The partial agonist activity of CA seen on PSA
stimulation in LNCaP cells could be due to this mutation.
However, the presence of the mutation in all sublines of
LNCaP and its effect on androgen responsive elements re-
main to be established.
The concept ofandrogen dependence of normal and malig-
nant prostatic cells has guided research and therapeutic
strategies since the pioneering work of Huggins and Hodges
(1941). Reduction ofcirculating testosterone from the normal
range of 3-6ngml-' of serum (= I x 10-8 M-2X 10-8M)
to about 0.3 ng ml' (= 1 x 10-9M) by surgical or to about
0.06 ngml-' (= 2 x 10-0M) by medical castration (Robin-
son & Thomas, 1971) leads to at least partial remission of
androgen-dependent cancers. Growth properties of LNCaP
cells characterised in this report and by others refute the
hypothesis of androgen dependence of this cell line. LNCaP
cells grow well in routine cell culture medium containing
about 0.02 ng ml'l (= 0.7 x 10i-0 M) testosterone and andro-
stenedione, respectively (Challis et al., 1974), i.e. far less than
sera of orchiectomised men (Robinson & Thomas, 1971).
Addition of 750ngml-' antiandrogen (= 1.8 x 10-6M CA
or 2.6 x 10-6 M Flu-OH) to this medium only slightly affects
cell proliferation (Figure 1). Addition of synthetic androgens
at concentrations which maximally stimulate the androgen
receptor (Veldscholte et al., 1990b) does not lead to stimula-
tion, but to inhibiton of cell growth (Table I). These results
unequivocally demonstrate androgen receptor-mediated nega-
tive control of proliferation in LNCaP cells. All experimental
data obtained with physiological androgen concentrations are
consistent with inhibition of proliferation triggered by an
androgen receptor-dependent mechanism. Since synthetic
derivatives of steroid hormones can act as directly cytotoxic
agents (Schulz et al., 1988a), we examined, whether the
inhibitory effect of synthetic androgens toward LNCaP cells
is specific for this androgen receptor positive cell type. All
control cell lines devoid of androgen receptors were in no
way affected by the androgens tested. No indication of a
cytotoxic mode of action was detected at the concentrations
of the synthetic hormones used. The slight inhibition of
LNCaP cells by 750 ng ml-' of antiandrogens may be due to
a partial agonist effect at the androgen receptor, as shown by
Veldscholte et al. (1990b) for CA. Since the neoplasm, from
which the LNCaP line originated, had only poorly responded
to androgen deprivation (Horoszewicz et al., 1980), an
androgen-dependent growth pattern of this cell line would
have required a major change of behaviour during the nude
mouse passages or the subsequent adaptation of the cells to
in vitro growth.
The most salient phenomenon is the androgen receptor-
mediated inhibition of cell proliferation and focus formation
in soft agar, which suggests the suppression of the trans-
formed phenotype. The finding of Sonnenschein et al. (1989)
that LNCaP cells do not grow in castrated male nude mice
implanted with a DHT pellet, is in accord with our result
demonstrating androgen-induced inhibition of anchorage-
independent growth of LNCaP cells in vitro. The effect of
synthetic androgens on tumour formation of LNCaP cells in
nude mice has not been investigated. In the vast majority of
cell types inability to grow in soft agar correlates with dras-
tically reduced tumourigenicity in an immunocompromised
host (Pollack et al., 1984; Freedman & Shin, 1974).
Induction of terminal differentiation of tumour cells in
vitro is accompanied by loss of mitotic activity and of the
transformed phenotype, and often involves a decrease in
c-myc expression (for a review, see Spencer & Groudine,
1990, and Reiss et al., 1986). The antiandrogens CA and
Flu-OH did not exhibit partial agonist, i.e. repressing,
activity on c-myc RNA levels. When androgens and anti-
androgens were applied together, the androgen-induced
repression of c-myc RNA was strongly antagonised. This
behaviour is in contrast to the stimulation of PSA mRNA,
where antiandrogens showed considerable androgenic
activity.
'"m W..
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Although no markers of differentiation in prostate
epithelium are known, the induction of five fundamental
changes in the behaviour of the cells (inhibition of prolifera-
tion; abrogation of anchorage-independent growth; morpho-
logical change; induction of Prostate Specific Antigen and
repression of c-myc) may indicate the entry of the cells into a
higher degree of differentiation. In some cell types at least,
down-regulation of c-myc is supposed to have a functional
role in the induction of differentiation, since the reduction of
c-myc RNA and protein levels by antisense nucleic acids can
trigger terminal differentiation in HL 60 cells (Holt et al.,
1988). It will be of interest to see, whether androgen-
inducible growth controlling genes (Klein, 1987; Sager, 1989)
are responsible for the unique reversion of malignant traits
and induction of a more highly differentiated phenotype in
LNCaP cells.
There are reports of so far inexplicable responses of pros-
tatic carcinoma patients to administration of testosterone
(Brendler et al., 1950; Prout & Brewer, 1967; Crowin et al.,
1970). In rare cares, testosterone along led to objective im-
provement of the patient's condition. LNCaP could provide
a useful in vitro model of an uncommon class of prostatic
cancer which responds favourably to androgen administra-
tion and contribute to the understanding of the molecular
mechanisms involved in the suppression of the transformed
phenotype.
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